Abstract
Summary
The electronic clinical outcome assessment (eCOA) solutions market is projected to reach USD 3.9 billion by 2029 from USD 1.8 billion in 2024, at a CAGR 16.6% during the forecast period. The the growing inclination towards digital data collection and analysis, an escalating need for economical data collection solutions, and the increasing integration of connected devices in healthcare institutions are the factors that will drive the growth of this market. On the other hand, the sensitivity of patient health data requires robust security measures. Concerns about data breaches, unauthorized access, or cybersecurity threats may impede the adoption of eCOA solutions to a certain extent over the forecast period.
“The BYOD (bring your own device) model segment is estimated to hold the major share in 2023, by type of wearable, mobile and other devices.”
The wearable, mobile and other devices market is bifurcated into BYOD (bring your own device) model, provisioned device model, and hybrid model. The BYOD model segment accounted for the largest market share during the forecast period. The growth of BYOD (Bring Your Own Device) adoption is driven by cost-effectiveness, as it eliminates the need for sponsors to manage dedicated devices, lowering trial costs. Patient familiarity with their own devices enhances user-friendliness, boosting engagement and data quality, while increasing accessibility for geographically dispersed and resource-limited patients, aligning with decentralized trials. Additionally, technological advancements in secure data encryption address security concerns, and evolving regulations favor secure BYOD implementation in certain regions, positioning it as a cost-efficient, patient-centric approach in clinical trials.
“Clinical trials segment is estimated to hold the largest share of electronic clinical outcome assessment (eCOA) solutions market, by application.”
Based on application, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into clinical trials, observational studies and real-world evidence (RWE) generation, patient management and registries, and other applications. The clinical trials segment is expected to hold the largest share during the forecast period. The rise of eCOA (Electronic Clinical Outcome Assessment) in clinical trials is driven by a myriad of advantages: heightened data quality achieved through real-time capture and minimized transcription errors, enhanced patient engagement facilitated by user-friendly platforms and improved data ownership, and increased trial efficiency through streamlined data collection and accelerated analysis. This results in superior-quality studies, increased patient satisfaction, and expedited drug development, positioning eCOA as the emerging gold standard for a more efficient, patient-centric future in clinical research.
“Electronic Observer-Reported Outcomes (EOBSRO) segment is expected to register highest growth in the forecast period, by product type segment.”
Based on product type, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into electronic patient-reported outcomes (EPRO), Electronic Clinician-reported outcomes (ECLINRO), electronic observer-reported outcomes (EOBSRO), and Electronic performance-reported outcomes (EPERFO). In 2023, the electronic observer-reported outcomes (EOBSRO) segment segment is expected to register highest growth in the forecast period. Observer-reported outcomes (ObsRO) play a crucial role in gathering real-world evidence outside controlled trial settings, informing post-market research and regulatory decisions. Effective patient monitoring in decentralized trials, improved data quality, availability of holistic picture of patient experience and treatment response are some of the factors that contribute to the growth of the segment.
“Asia Pacific to register the highest growth in the electronic clinical outcome assessment (eCOA) solutions market in the forecast period.”
The global electronic clinical outcome assessment (eCOA) solutions market is segmented into four major regions, namely, North America, Europe, APAC, and the Rest of the World. In 2022, Asia Pacific was expected to register the highest growth for electronic clinical outcome assessment (eCOA) solutions systems in the forecast period. Factors such as increasing healthcare expenditure, developing healthcare infrastructure, rising demand for digital solutions in healthcare sector, large patient population, increasing focus on patient-centric care and the need for better data collection and analysis are expected to drive the growth of the electronic clinical outcome assessment (eCOA) solutions market in the Asia Pacific.
Breakdown of the supply-side, demand side, primary interviews by company type, designation, and region:
• By Supply Side: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
• By Demand Side: Hospital Directors/VPs/Managers/Department Heads (40%), Pharma & Biopharma Company’s Product managers, Purchase Heads, etc. (35%), and Others (25%).
• By Designation: C-level Executives (31%), Director-level (25%), and Managers (44%)
• By Region: North America (45%), Europe (20%), Asia Pacific (28%), and RoW (4%)
The prominent players in this market are Koninklijke Signant Health (US), IQVIA Holdings, Inc. (US), Oracle (US), Clario (US), Medable Inc. (US), Medidata (US), Merative (US), ICON plc (Ireland), Paraxel International (MA) Corporation (US), Climedo Health GmbH (Germany), Healthentia (Belgium), Veeva Systems (US), assisTek (US), Curebase Inc. (US), Castor (US), EvidentIQ Group GmbH (Germany), YPrime, LLC. (US), Clinical ink (US), Clinion (US), Kayentis (France), TransPerfect (US), ObvioHealth USA, Inc. (US), WCG Clinical (Germany), ClinCapture (US), and Cloudbyz (US). Players adopted organic as well as inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.
Research Coverage
• The report studies the electronic clinical outcome assessment (eCOA) solutions market based on component, product type, deployment model, application area, end user, and region.
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
• The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total electronic clinical outcome assessment (eCOA) solutions market.
• The report forecasts the revenue of market segments with respect to five major regions.
Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.
This report provides insights into the following pointers:
Analysis of key drivers (increasing R&D expenditure for product development by medtech, and pharma-biotech companies, rising operational costs and regulatory requirements associated with clinical research studies, favorable government support and funding for clinical trials, growing prevalence of chronic diseases & subsequent increase in clinical trials, effective monitoring of clinical data, reduction in overall costs and timelines of clinical trials), restraints (lack of skilled professionals to develop and operate eCOA solutions, high implementation and maintenance cost, lack of awareness about eCOA solutions among end users), opportunities (surging eCOA adoption owing to increasing number of clinical trials in emerging economies, growing outsourcing of clinical trial processes to CROs, gradual shift from manual data interpretation to real-time data analysis, growing penetration of mobile technology in healthcare industry), and challenges (evolving regulatory landscape and compliance requirements, interoperability & integration, data security & privacy issues, resistance from traditional healthcare professionals and concerns regarding software reliability) influencing the growth of electronic clinical outcome assessment (eCOA) solutions market.
Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the electronic clinical outcome assessment (eCOA) solutions market.
Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of electronic clinical outcome assessment (eCOA) solutions solutions across regions.
Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the electronic clinical outcome assessment (eCOA) solutions market.
Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the electronic clinical outcome assessment (eCOA) solutions market.
Table of Contents
1 INTRODUCTION 58
1.1 STUDY OBJECTIVES 58
1.2 MARKET DEFINITION 58
1.2.1 INCLUSIONS & EXCLUSIONS 59
1.3 MARKET SCOPE 60
1.3.1 MARKET SEGMENTATION 60
1.3.2 REGIONAL SCOPE 61
1.4 YEARS CONSIDERED 61
1.4.1 CURRENCY CONSIDERED 62
1.5 STAKEHOLDERS 62
1.6 RECESSION IMPACT 62
2 RESEARCH METHODOLOGY 63
2.1 RESEARCH DATA 63
2.2 SECONDARY SOURCES 64
2.2.1 KEY DATA FROM SECONDARY SOURCES 65
2.3 PRIMARY DATA 65
2.3.1 PRIMARY SOURCES 66
- 2.3.1.1 Key data from primary sources 67
- 2.3.1.2 Key industry insights 68
2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS 68
2.4 RESEARCH METHODOLOGY DESIGN 69
2.5 MARKET SIZE ESTIMATION 69
2.5.1 BOTTOM-UP APPROACH 71
2.5.2 TOP-DOWN APPROACH 72
2.6 MARKET BREAKDOWN & DATA TRIANGULATION 77
2.7 ASSUMPTIONS 78
2.7.1 MARKET SIZING ASSUMPTIONS 78
2.7.2 OVERALL STUDY ASSUMPTIONS 78
2.8 LIMITATIONS 79
2.8.1 SCOPE-RELATED LIMITATIONS 79
2.8.2 METHODOLOGY-RELATED LIMITATIONS 79
2.9 RISK ASSESSMENT 79
2.10 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: RECESSION IMPACT ANALYSIS 79
3 EXECUTIVE SUMMARY 81
4 PREMIUM INSIGHTS 88
4.1 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET OVERVIEW 88
4.2 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT AND COUNTRY (2023) 89
4.3 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 90
4.4 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: REGIONAL MIX (2021-2029) 91
4.5 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DEVELOPED VS. EMERGING ECONOMIES 92
5 MARKET OVERVIEW 93
5.1 INTRODUCTION 93
5.2 MARKET DYNAMICS 93
5.2.1 MARKET DYNAMICS: IMPACT ANALYSIS 94
5.2.2 DRIVERS 95
- 5.2.2.1 Increasing R&D expenditure for product development by medtech and pharma-biotech companies 95
- 5.2.2.2 Rising operational costs and regulatory requirements associated with clinical research studies 96
- 5.2.2.3 Favorable government support and funding for clinical trials 96
- 5.2.2.4 Growing prevalence of chronic diseases & subsequent increase in clinical trials 97
- 5.2.2.5 Effective monitoring of clinical data 98
- 5.2.2.6 Reduction in overall costs and timelines of clinical trials 98
5.2.3 RESTRAINTS 98
- 5.2.3.1 Dearth of skilled professionals to develop and operate eCOA solutions 98
- 5.2.3.2 High implementation and maintenance costs 99
- 5.2.3.3 Lack of awareness about eCOA solutions among end users 99
5.2.4 OPPORTUNITIES 100
- 5.2.4.1 Surging eCOA adoption owing to increasing number of clinical trials in emerging economies 100
- 5.2.4.2 Growing outsourcing of clinical trial processes to CROs 100
- 5.2.4.3 Gradual shift from manual data interpretation to real-time data analysis 101
- 5.2.4.4 Growing penetration of mobile technology in healthcare industry 102
5.2.5 CHALLENGES 102
- 5.2.5.1 Evolving regulatory landscape and compliance requirements 102
- 5.2.5.2 Concerns regarding data security & privacy 103
- 5.2.5.3 Lack of interoperability & integration 104
- 5.2.5.4 Resistance from traditional healthcare professionals and concerns regarding software reliability 104
6 INDUSTRY INSIGHTS 106
6.1 INTRODUCTION 106
6.2 OVERVIEW OF KEY INDUSTRY TRENDS 106
6.2.1 RISING NUMBER OF DECENTRALIZED CLINICAL TRIALS 106
6.2.2 INCREASED FOCUS ON REAL-WORLD DATA (RWD) 107
6.3 VALUE/SUPPLY CHAIN ANALYSIS 108
6.4 ECOSYSTEM ANALYSIS 109
6.5 TECHNOLOGY ANALYSIS 109
6.5.1 KEY TECHNOLOGIES 109
- 6.5.1.1 Machine learning 109
- 6.5.1.2 Artificial intelligence 110
- 6.5.1.3 Internet of things 110
- 6.5.1.4 Integrated APIs 110
6.5.2 COMPLEMENTARY TECHNOLOGIES 111
- 6.5.2.1 Interactive Voice Response (IVR) 111
- 6.5.2.2 Data analytics 111
- 6.5.2.3 Telehealth 111
6.5.3 ADJACENT TECHNOLOGIES 112
- 6.5.3.1 Cloud computing 112
- 6.5.3.2 Blockchain 112
6.6 REGULATORY LANDSCAPE 112
6.6.1 REGULATORY ANALYSIS 112
- 6.6.1.1 North America 112
- 6.6.1.2 Europe 114
- 6.6.1.3 Asia Pacific 114
- 6.6.1.4 Latin America 115
- 6.6.1.5 Middle East & Africa 115
6.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116
6.7 PORTER’S FIVE FORCES ANALYSIS 118
6.7.1 COMPETITIVE RIVALRY 119
6.7.2 BARGAINING POWER OF BUYERS 119
6.7.3 BARGAINING POWER OF SUPPLIERS 119
6.7.4 THREAT OF SUBSTITUTES 119
6.7.5 THREAT OF NEW ENTRANTS 119
6.8 PRICING ANALYSIS 120
6.8.1 AVERAGE SELLING PRICE TREND, BY REGION 121
6.8.2 INDICATIVE PRICING ANALYSIS, BY PRODUCT 121
6.9 CASE STUDY ANALYSIS 122
6.9.1 CASE 1: A LEADING ACADEMIC MEDICAL CENTER MONITORS NEWLY DIAGNOSED MYELOMA PATIENTS WITH MEDIDATA ECOA 122
6.9.2 CASE 2: SIGNANT’S SCALE MANAGEMENT EXPERTISE FACILITATES ENDPOINT ACCURACY & RELIABILITY IN PSORIATIC ARTHRITIS TRIAL 123
6.10 PATENT ANALYSIS 124
6.11 KEY CONFERENCES & EVENTS, 2023-2024 128
6.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 129
6.13 KEY STAKEHOLDERS & BUYING CRITERIA 130
6.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 130
6.13.2 BUYING CRITERIA 131
6.14 END-USER ANALYSIS 131
6.14.1 UNMET NEEDS 131
6.14.2 END-USER EXPECTATIONS 133
6.15 REVENUE MODEL ANALYSIS 133
6.15.1 SUBSCRIPTION-BASED MODEL 133
6.15.2 PAY-PER-STUDY MODEL 134
6.15.3 CUSTOMIZED SOLUTIONS MODEL 134
6.15.4 SOFTWARE-AS-A-SERVICE (SAAS) MODEL 134
6.15.5 CONSULTING AND INTEGRATION SERVICES MODEL 134
6.16 INVESTMENT LANDSCAPE 135
7 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT 136
7.1 INTRODUCTION 137
7.2 SOFTWARE 138
7.2.1 ADVANTAGES OF ECOA SOFTWARE LIKE REAL-TIME ANALYSIS AND STREAMLINED DATA COLLECTION TO FOSTER MARKET GROWTH 138
7.3 SERVICES 140
7.3.1 ABILITY OF ECOA SERVICES TO REDUCE TIME AND COST OF CLINICAL TRIAL PROCESSES TO BOOST DEMAND 140
7.4 WEARABLES, MOBILE DEVICES, AND OTHER DEVICES 142
7.4.1 BRING YOUR OWN DEVICE (BYOD) MODEL 145
- 7.4.1.1 Ability of BYOD models to increase flexibility and convenience to drive adoption 145
7.4.2 PROVISIONED DEVICE MODEL 147
- 7.4.2.1 Growing need for standardization and control in data collection process to support market growth 147
7.4.3 HYBRID MODEL 149
- 7.4.3.1 Ability of hybrid models to increase balance between standardization and participant preferences to favor growth 149
8 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT 152
8.1 INTRODUCTION 153
8.2 ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) 154
8.2.1 GROWING EMPHASIS ON PATIENT-CENTRIC HEALTHCARE TO BOOST MARKET GROWTH 154
8.3 ELECTRONIC OBSERVER-REPORTED OUTCOMES (EOBSRO) 156
8.3.1 GROWING NEED FOR ACCURATE AND RELIABLE DATA COLLECTION TO DRIVE ADOPTION OF EOBSRO SOLUTIONS 156
8.4 ELECTRONIC CLINICIAN-REPORTED OUTCOMES (ECLINRO) 158
8.4.1 INCREASING EFFICACY AND ACCURACY IN CAPTURING CLINICIAN-REPORTED DATA TO PROPEL GROWTH 158
8.5 ELECTRONIC PERFORMANCE-REPORTED OUTCOME (EPERFO) 160
8.5.1 INCREASING ACCESSIBILITY AND FLEXIBILITY IN CLINICAL TRIAL SETTINGS TO BOOST MARKET 160
9 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL 163
9.1 INTRODUCTION 164
9.2 ON-PREMISE MODEL 164
9.2.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE 164
9.3 WEB-HOSTED & CLOUD-BASED MODEL 166
9.3.1 ENHANCED QUALITY OF CLINICAL TRIALS WITH IMPROVED PRODUCTIVITY TO DRIVE MARKET 166
9.4 HYBRID MODEL 168
9.4.1 ABILITY TO OFFER BALANCED SOLUTIONS USING HYBRID MODEL TO SUPPORT MARKET GROWTH 168
10 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION 171
10.1 INTRODUCTION 172
10.2 CLINICAL TRIALS 173
10.2.1 ONCOLOGY 176
- 10.2.1.1 Rising incidence of cancer to drive market growth 176
10.2.2 INFECTIOUS DISEASES 179
- 10.2.2.1 Growing focus on infectious disease treatment and management to boost market 179
10.2.3 NEUROLOGY 181
- 10.2.3.1 Increasing investments in R&D and grants for neurological disorders to drive market 181
10.2.4 METABOLIC DISORDERS 183
- 10.2.4.1 Rising diabetes incidence to drive market 183
10.2.5 IMMUNOLOGY 185
- 10.2.5.1 Increasing development of immunology drugs to drive demand for eCOA solutions 185
10.2.6 CARDIOVASCULAR DISEASES 187
- 10.2.6.1 Need for efficient and reliable means of collecting patient-reported outcomes in cardiovascular trials to support growth 187
10.2.7 RARE DISEASES & GENETIC DISORDERS 189
- 10.2.7.1 Growing government support for rare diseases & genetic disorders to boost market 189
10.2.8 MENTAL HEALTH DISORDERS 191
- 10.2.8.1 Growing awareness of mental health disorders to contribute to market growth 191
10.2.9 OTHER THERAPEUTIC AREAS 193
10.3 OBSERVATIONAL STUDIES & REAL-WORLD EVIDENCE (RWE) GENERATION 195
10.3.1 GROWING RECOGNITION OF BENEFITS OF REAL-WORLD EVIDENCE GENERATION TO DRIVE DEMAND 195
10.4 PATIENT MANAGEMENT & REGISTRIES 197
10.4.1 EVOLVING LANDSCAPE OF PATIENT-CENTRIC HEALTHCARE TO DRIVE SEGMENTAL GROWTH 197
10.5 OTHER APPLICATIONS 199
11 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER 202
11.1 INTRODUCTION 203
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 204
11.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 204
11.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) 206
11.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET 206
11.4 GOVERNMENT ORGANIZATIONS 208
11.4.1 GROWING COLLABORATIONS BETWEEN GOVERNMENT ORGANIZATIONS AND CROS TO PROPEL GROWTH 208
11.5 MEDTECH COMPANIES 210
11.5.1 GROWING UTILIZATION OF CLINICAL DATA SOFTWARE SOLUTIONS FOR MEDICAL DEVICE TRIALS TO FUEL GROWTH 210
11.6 HOSPITALS & HEALTHCARE PROVIDERS 212
11.6.1 INCREASING IT BUDGETS TO STREAMLINE PATIENT DATABASES TO PROPEL MARKET GROWTH 212
11.7 ACADEMIC & RESEARCH INSTITUTES 214
11.7.1 FAVORABLE GOVERNMENT SUPPORT FOR CLINICAL RESEARCH TO SUPPORT MARKET GROWTH 214
11.8 CONSULTING SERVICE COMPANIES 216
11.8.1 GROWING COLLABORATIONS BETWEEN CONSULTANCY FIRMS AND PHARMA & BIOTECH COMPANIES TO DRIVE MARKET 216
12 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION 219
12.1 INTRODUCTION 220
12.2 NORTH AMERICA 221
12.2.1 NORTH AMERICA: RECESSION IMPACT 229
12.2.2 US 230
- 12.2.2.1 Rising government funding for pharmaceutical R&D to drive market 230
12.2.3 CANADA 237
- 12.2.3.1 Increasing number of clinical trials to support market growth 237
12.3 EUROPE 244
12.3.1 EUROPE: RECESSION IMPACT 252
12.3.2 GERMANY 253
- 12.3.2.1 Increase in R&D expenditure and clinical trials to boost market growth 253
12.3.3 UK 259
- 12.3.3.1 Growing investments in drug discovery services to favor market growth 259
12.3.4 FRANCE 266
- 12.3.4.1 Growing R&D pipeline for oncology trials to drive market 266
12.3.5 ITALY 273
- 12.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake 273
12.3.6 REST OF EUROPE 280
12.4 ASIA PACIFIC 287
12.4.1 ASIA PACIFIC: RECESSION IMPACT 296
12.4.2 JAPAN 297
- 12.4.2.1 Established clinical trial infrastructure and increase in funds for R&D to support growth 297
12.4.3 CHINA 303
- 12.4.3.1 Low cost of clinical trials and large pharmaceutical R&D base to drive market 303
12.4.4 INDIA 310
- 12.4.4.1 Growing pharmaceutical industry to fuel uptake of eCOA solutions 310
12.4.5 REST OF ASIA PACIFIC 317
12.5 LATIN AMERICA 324
12.5.1 LARGE POOL OF PHARMACEUTICAL COMPANIES TO FAVOR MARKET GROWTH 324
12.5.2 LATIN AMERICA: RECESSION IMPACT 331
12.6 MIDDLE EAST & AFRICA 332
12.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 339
12.6.2 GCC COUNTRIES 340
- 12.6.2.1 Increase in healthcare investments to support market growth 340
12.6.3 REST OF MIDDLE EAST & AFRICA 347
13 COMPETITIVE LANDSCAPE 355
13.1 OVERVIEW 355
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 355
13.3 REVENUE ANALYSIS 357
13.4 MARKET SHARE ANALYSIS 358
13.5 BRAND/SOFTWARE COMPARATIVE ANALYSIS 360
13.5.1 MEDIDATA (US) 360
13.5.2 IQVIA (US) 361
13.5.3 ICON PLC (IRELAND) 361
13.5.4 SIGNANT HEALTH (US) 361
13.5.5 CLARIO (US) 361
13.6 VALUATION AND FINANCIAL METRICS OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS VENDORS 362
13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS 363
13.7.1 STARS 363
13.7.2 EMERGING LEADERS 363
13.7.3 PERVASIVE PLAYERS 363
13.7.4 PARTICIPANTS 363
13.7.5 COMPANY FOOTPRINT ANALYSIS 365
13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES 370
13.8.1 PROGRESSIVE COMPANIES 370
13.8.2 DYNAMIC COMPANIES 370
13.8.3 RESPONSIVE COMPANIES 370
13.8.4 STARTING BLOCKS 370
13.8.5 COMPETITIVE BENCHMARKING 372
13.9 COMPETITIVE SCENARIO 374
14 COMPANY PROFILES 376
14.1 KEY PLAYERS 376
14.1.1 MEDIDATA (A DASSAULT SYSTÈMES COMPANY) 376
14.1.2 IQVIA 380
14.1.3 SIGNANT HEALTH 383
14.1.4 CLARIO 386
14.1.5 ICON PLC 389
14.1.6 ORACLE CORPORATION 393
14.1.7 MEDABLE INC 396
14.1.8 MERATIVE L.P 398
14.1.9 PAREXEL INTERNATIONAL (MA) CORPORATION 399
14.1.10 CLIMEDO HEALTH GMBH 401
14.1.11 HEALTHENTIA (A PRODUCT OF INNOVATION SPRINT) 402
14.1.12 VEEVA SYSTEMS 403
14.1.13 ASSISTEK 406
14.1.14 CUREBASE INC 408
14.1.15 CASTOR 409
14.1.16 EVIDENTIQ GROUP GMBH 411
14.1.17 YPRIME, LLC 412
14.1.18 CLINICAL INK 414
14.1.19 CLINION 416
14.1.20 KAYENTIS 417
14.2 OTHER PLAYERS 419
14.2.1 TRANSPERFECT 419
14.2.2 OBVIOHEALTH USA, INC 419
14.2.3 WCG CLINICAL 420
14.2.4 СLINСAPTURE 420
14.2.5 CLOUDBYZ 421
15 APPENDIX 422
15.1 DISCUSSION GUIDE 422
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 429
15.3 CUSTOMIZATION OPTIONS 431
15.4 RELATED REPORTS 431
15.5 AUTHOR DETAILS 432